Latest Medical Discoveries

Arc Institute's State transformer forecasts gene-expression responses in cell types it never trained on.

A telomere-to-telomere HG002 benchmark covering the diploid genome's hardest regions

In vivo editing of the PCSK9 gene produced durable cholesterol reductions in an early-stage trial.

Mass spec measures fluctuation energies for 5,778 protein domains in parallel

Ancient-DNA time series reveal hundreds of alleles under directional selection in humans

Nine trillion base pairs of training, a megabase of context, single-nucleotide resolution.

A precise single-letter edit reawakens protective fetal hemoglobin without cutting DNA.

After a personalized neoantigen mRNA vaccine, 11 of 14 TNBC patients stayed relapse-free for up to six years

One model predicts thousands of regulatory genomic tracks and tops specialist tools on variant effects.

Bimagrumab plus semaglutide produced greater weight loss than either drug alone in a phase 2 trial

Five genomic factors explain most shared genetic risk across 14 psychiatric disorders

A generative model scaffolds enzyme active sites from functional-group positions alone, no residue order required.

Drug-loaded nanoparticles hijack skull immune cells to bypass the blood-brain barrier for stroke therapy

A generative model builds active metallohydrolases straight from chemistry, no lab tinkering required.

An open pipeline turns AlphaFold2 into nanomolar binders without high-throughput screening.

A single-cell map of bone-innervating sensory neurons identifies FGF9 as a driver of fracture repair

High-dimensional profiling reveals how a gene-edited pig organ is rejected, and how it holds.

An in vivo edit of the liver ANGPTL3 gene lowered triglycerides and LDL in a phase 1 trial.

A once-daily small-molecule drug cut body weight by double digits in a large phase 3 obesity trial.

A language model invented OpenCRISPR-1, a Cas9 hundreds of mutations from anything in nature.

A computational method builds small proteins programmed to recognize chosen DNA targets and control nearby genes.

Haplotype-resolved assemblies close most remaining gaps and fully sequence 1,246 centromeres.

A targeted nanoparticle reprograms T cells into cancer fighters, skipping the factory.

The first personalized in vivo base-editing medicine, from diagnosis to dosing in about six months.

Long-term follow-up shows vaccine-induced T cells persist and track with delayed recurrence.

Generative AI builds serine hydrolases with efficiencies approaching natural proteins.

A single infusion of stem-cell-derived islets restored insulin independence in most recipients.